Halaven price in Italy likely to be higher than UK price rejected by NICE
This article was originally published in Scrip
Executive Summary
As Eisai considers how to respond to negative funding recommendations in England for Halaven, its end of life breast cancer drug, the company says it is not expecting such a bumpy ride elsewhere. Eventual approval from the Scottish Medicines Consortium looks likely, while reimbursement assessment is approaching in Italy, and at a better price than that offered in the UK, Nick Burgin, the company's European director of market access, told Scrip.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.